UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 28, 2010

MusclePharm Corporation
(Exact Name of Registrant as Specified in its Charter) 

 Nevada 000-53166 77-0664193
(State or Other Jurisdiction (Commission File No.) (I.R.S. Employer
 of Incorporation) Identification
 Number)

 4721 Ironton Street, Denver, Colorado 80239
 (Address of Principal Executive Offices) (Zip Code)


 Registrant's telephone number, including area code: (800) 210-7369

3390 Peoria Street, #307, Aurora, Colorado 80010
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act


(17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act


(17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

On October 28, 2010, the Company issued a press release reporting their preliminary financial results for the third quarter ending September 30, 2010. The press release has been attached hereto as an exhibit and will also be posted on the Company's website: www.musclepharm.com.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial Statements of Businesses Acquired.

Not Applicable.

(b) Pro Forma Financial Information

Not Applicable.

(c) Shell Company Transactions

Not Applicable. 

(d) Exhibits

 Exhibit 99.1 Press Release dated October 28, 2010 - MusclePharm
 Reports Preliminary Third Quarter 2010 Results

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MusclePharm Corporation 

 By: /s/ Brad Pyatt
 Name: Brad Pyatt
 Title: Chief Executive Officer
Dated: October 28, 2010

Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Muscle Pharm (CE) Charts.
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Muscle Pharm (CE) Charts.